Aurora Cannabis completely rules out previously announced contract finance greenshoe option


EDMONTON, AB, January 26, 2021 / CNW / – Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE: ACB) (TSX: ACB), the Canadian company that defines the future of cannabinoids worldwide, today announced the completion of its previously announced purchase Offering (the “Offering”) shares in the Company (the “Shares”) for all of the gross proceeds of $ 137,940,000. The company sold 13,200,000 units at a price of US $ 10.45 per share, including 1,200,000 shares that were fully sold upon exercise, to the full amount of the subscribers’ over-allotment option.

Each Unit consists of one common share of the Company (a “Common Share”) and one half of a warrant to purchase one common share of the Company (each complete warrant to purchase one common share, a “Warrant”). Each warrant may be exercised to purchase one common share of the Company (a “Warrant Share”) for a period of 36 months from the closing date of the offering at an exercise price of $ 12.60 per warrant share, subject to adjustment in certain cases.

BMO Capital Markets and ATB Capital Markets acted as bookrunners for the offer.

The company plans to use the net proceeds of the offering for general corporate purposes, including opportunistic deleveraging. The company believes the offering fits in with its broader strategy of having a strong balance sheet while maintaining maximum investment flexibility and a leadership position in global cannabinoids.

In connection with the Offering, the Company filed a prospectus addendum (the “Prospectus Addendum”) to the Company’s short-form base shelf prospectus dated October 28, 2020 (the “Base Shelf Prospectus”) with the securities commissions or similar securities regulators in each of the provinces of Canada, except Quebecand with the US Securities and Exchange Commission (“SEC”) as part of the company’s registration statement on Form F-10 (“Registration Statement”) under the US / Canada Multijurisdictional Disclosure System. The prospectus supplement, the base shelf prospectus and the registration declaration contain important detailed information about the company and the offer.

Copies of the Supplement and the Base Shelf Prospectus are available from SEDAR at Copies of the Supplement to the Prospectus and the Registration Statement are available from EDGAR at Copies of the Supplementary Prospectus, Base Prospectus and Registration Statement are also available from BMO Capital Markets by contacting BMO Capital Markets, Brampton Distribution Center, C / O, Data Group of Companies, 9195 Torbram Road. Brampton, Ontario, L6S 6H2 or by phone at (905) 791-3151 ext. 431 or by email at [email protected] or from BMO Capital Markets Corp., Attn: Equity Consortium Department, 3 Times Square, 25th floor, New York, NY 10036 (Attn: Equity Syndicate) or by phone at (800) 414-3627 or by email at [email protected]. Copies of such documents are also available from ATB Capital Markets Inc., Attn: Gail O’Connor410-585 8th Ave SW, Calgary, Alberta, T2P 1G1, (403) 539-8629 or by email from [email protected].

No securities regulatory authority has approved or disapproved the contents of this press release. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy, nor will any sale of these securities be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Aurora

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquarters in Edmonton, AlbertaAurora is a pioneer in global cannabis helping people improve their lives. The company’s portfolio of brands includes Aurora, Aurora Drift, San Rafael ’71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler and Reliva CBD. Aurora’s brands provide innovative, high quality cannabis products to their customers and continue to be industry leaders in medical, performance, wellness and recreation wherever they are introduced. For more information, please visit our website at

Aurora common stock trades on the TSX and NYSE under the symbol “ACB” and is a constituent of the S & P / TSX Composite Index.

Forward-Looking Statements

This press release contains statements that contain certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are often identified by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential” “,” suggested “and other similar words or statements suggest that certain events or conditions” may “or” will “occur. Forward-looking statements made in this press release include statements regarding the expected use of the proceeds of the offering. These forward-looking statements are only predictions. Various assumptions have been made in order to reach conclusions or to predict the forward-looking statements contained in this press release. Forward-looking statements are based on the opinions, estimates and assumptions of the management in the light of the experience of the management and the perception of historical trends, current conditions and expected developments at the time the statements are made, such as current and future market conditions, the ability to maintain them. Cost is in line with current expectations, the ability to generate high margin income in the Canadian consumer market, current and future regulatory environments, and future permits and permits. Forward-looking statements are subject to a number of risks, uncertainties and other factors that management believes are relevant and appropriate in the given circumstances and that could cause actual events, results, levels of activity, performance, prospects, opportunities or successes to differ materially from them projected in the forward-looking statements, including the risks associated with entering the U.S. market, the ability to realize the anticipated benefits related to the Reliva acquisition, the achievement of Aurora’s business transformation plan, general business and economic conditions, Legislative changes and regulations, product demand, changes in the price of goods required, competition, effects and responses to the COVID-19 pandemic and other risks, uncertainties and factors dated under the heading “Risk Factors” on the company’s annual information form September 24, 2020 (the “AIF”) and filed with the Canadian Securities and Exchange Commission, which are available on the Company’s Issuer Profile on SEDAR at and on the SEC’s website at for use of the proceeds from the Change offer. The company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and that other factors could also affect results. Readers are cautioned to carefully consider the risks, uncertainties and assumptions in evaluating any forward-looking statements and are cautioned not to place undue reliance on such information. The company is under no obligation and expressly disclaims any intention or obligation to update or revise forward-looking statements as a result of new information, future events or for other reasons, unless this is expressly required by the applicable securities law.

SOURCE Aurora Cannabis Inc.

For more information: For the media: Michelle Lefler VP, Communications & PR [email protected];; For investors: ICR, Inc., Investor Relations, [email protected]

similar links

Comments are closed.